At the 2022 ASCO annual meeting, Matthew Goetz, MD, Mayo Clinic, Rochester, MN, discusses recent research presented at the 2022 ASCO annual meeting related to therapeutic options for breast cancer. Dr Goetz discusses CDK4/6 inhibitors and options for patients following progression on a CDK4/6 inhibitor.
More Videos in Metastatic Breast Cancer Content Hub
In this video, Sarah DiGeronimo, NP, and Sydney Smith, PharmD, both from Dana-Farber Cancer Institute, Boston, Massachusetts, discuss tips for the management of common side effects resulting from…
Sramila Aithal, MD, medical oncologist, Cancer Treatment Centers of America, discusses optimization of therapy for patients with HER2-positive metastatic breast cancer. Dr Authal shares her experience with toxicity…
Approximately 30% of women with early-stage breast cancer will face metastatic disease, and 6% are diagnosed with metastatic breast cancer initially. Living with metastatic breast cancer can elicit…
Barbara Pistilli, MD, chair of the breast cancer unit, Gustave Roussy, Villejuif, France, provides a case-based discussion of therapeutic options for a patient with pretreated HR+/HER2- (IHC 0)…
Lobular breast cancer presents unique challenges in detection and treatment due to its diffuse growth pattern and differences from ductal cancers. Liz O’Riordan, MD, shares her personal journey,…
This webinar, focused on challenging cases in metastatic breast cancer, was moderated by Ashkan Lashkari, MD, oncologist at Wellness Oncology, California, and included expert panelists Rebecca A. Shatsky,…
In this video, Frédérique Penault-Llorca, MD, PhD, professor of pathology, University of Clermont-Ferrandand, France, and Aditya Bardia, MD, MPH, director of translational research integration, UCLA, discuss the current…
Part 2 – Case Discussion Gabriel N. Mannis, MD, presents the case of patient “J.A.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Daniel A.…
Tufia C. Haddad, MD, an oncologist at Mayo Clinic, Rochester, Minnesota, discusses what to expect before, during, and after initial treatment for metastatic breast cancer. Dr Haddad emphasizes…